Table 2.

Details of MS and NMO patients.

Patient No.	Age (year)/gender	Disease dur (month)	Dur to the last relapse	EDSS	No. of relapse
MS-01	26/M	23	25	2.5	3
MS-02	53/M	51	20	2.5	3
MS-03	45/F	40	57	0	3
MS-04	33/F	30	33	1.5	3
MS-05	39/F	38	7	3	2
MS-06	32/M	27	59	0	3
MS-07	48/F	42	68	2.5	2
MS-08	18/F	14	44	3.5	2
MS-09	26/F	24	18	0	3
MS-10	49/F	45	48	2	2
MS-11	25/F	20	59	2.5	10
MS-12	24/M	21	39	0	4
MS-13	34/F	31	42	1	1
MS-14	16/F	14	21	1.5	6
MS-15	46/F	39	85	1	5
MS-16	25/M	23	22	3	2
MS-17	40/M	34	75	2	2
MS-18	42/F	41	16	2	3
MS-19	24/M	24	3	3.5	2
MS-20	42/F	39	43	3.5	5
MS-21	29/F	24	67	3	2
MS-22	34/F	31	34	2.5	1
MS-23	44/F	36	102	0	7
MS-24	26/F	23	44	5	2
MS-25	17/F	6	143	0	5
NMO-01	24/F	15	114	3	7
NMO-02	20/F	16	55	1.5	4
NMO-03	30/F	22	95	2	6
NMO-04	55/F	53	30	5.5	3
NMO-05	22/F	19	38	3.5	4
NMO-06	14/M	13	18	6.5	5
NMO-07	51/F	48	43	3	6
NMO-08	36/F	24	150	1.5	6
NMO-09	46/F	37	108	2.5	3
NMO-10	26/M	22	40	1	6
NMO-11	55/F	47	88	6.5	5
NMO-12	50/F	35	180	1.5	7
NMO-13	19/M	16	30	1.5	4
NMO-14	34/F	22	15	3.5	5
NMO-15	31/F	24	82	3.5	8
NMO-16	43/M	36	107	1	3
NMO-17	37/F	31	71	3.5	6
NMO-18	29/F	27	14	2	3
NMO-19	39/F	29	122	6	4
NMO-20	34/M	30	44	6	4
NMO-21	53/F	29	258	5.5	2
NMO-22	32/F	26	73	3	4
NMO-23	40/F	40	2	2.5	2
NMO-24	52/F	50	23	3	3
NMO-25	48/F	45	13	2	2
NMO-26	24/F	20	46	3	4
NMO-27	38/F	31	83	3.5	5
NMO-28	23/F	21	23	1	3
NMO-29	13/F	11	15	1.5	6
NMO-30	45/F	42	29	2	4

No, number; F, female; M, male; EDSS, expanded disability status scales; Dur, duration.